Mark Piskadlo
About Mark Piskadlo
Mark Piskadlo is the Vice President of Cell Therapy Manufacturing at Bristol Myers Squibb, with extensive experience in pharmaceutical and medical device industries.
Title
Mark Piskadlo is the Vice President of Cell Therapy Manufacturing at Bristol Myers Squibb in Summit, New Jersey, United States.
Current Role at Bristol Myers Squibb
Mark Piskadlo currently works as the Vice President, Cell Therapy Manufacturing at Bristol Myers Squibb. In this role, he oversees cell therapy manufacturing processes, ensuring the production of high-quality biologic products. He is involved in developing and implementing strategies to ensure the safety and efficacy of investigational medicines.
Previous Roles in the Industry
Before becoming Vice President at Bristol Myers Squibb, Piskadlo held several roles in the pharmaceutical and medical device industries. He served as the Head of Operational Excellence at Bristol Myers Squibb from 2019 to 2022. He also worked at Thermo Fisher Scientific as Sr. Director of Operations and Site Head from 2016 to 2019. Additionally, he has experience from roles at Sanofi, Roche Molecular Systems, and other companies.
Educational Background
Mark Piskadlo studied Operations Management and achieved an MBA from New Jersey Institute of Technology and Rutgers University (2002-2006). He also holds a BS in Biology with a Chemistry Minor from the same institutions (1996-2001). He has certifications in Six Sigma Black Belt and Lean Manufacturing from Villanova University in 2006.
Industry Expertise and Contributions
Piskadlo has extensive experience in cultural transformation within the pharmaceutical and medical device industries. He has a deep understanding of implementing organizational strategy in biologics and medical device manufacturing. His efforts include developing Risk Evaluation and Mitigation Strategies (REMS) and supporting patient access initiatives, highlighting his commitment to advancing health equity and innovative solutions in healthcare.